# AVEN

## Overview
AVEN is a gene that encodes the apoptosis and caspase activation inhibitor protein, which plays a pivotal role in regulating programmed cell death. This protein is categorized as an anti-apoptotic factor due to its ability to inhibit the activation of caspases, thereby preventing apoptosis. It achieves this by interacting with key apoptotic regulators such as apoptotic protease activating factor 1 (Apaf-1) and Bcl-xL, which are crucial for the execution of apoptosis (Muther2017An; Assem2009Aven). The AVEN protein is predominantly localized in the cytoplasm, where it exerts its protective effects against cell death, contributing to cellular homeostasis and survival. Its expression is tightly regulated by microRNAs, and it is involved in various cellular processes, including DNA damage response and translational regulation, through interactions with proteins and nucleic acids (Muther2017An; Thandapani2015Aven). The dysregulation of AVEN has been implicated in several cancers, highlighting its clinical significance in oncology (Baranski2015Aven‐mediated; Thandapani2015Aven).

## Function
The AVEN gene encodes a protein that functions as an inhibitor of apoptosis, a critical process of programmed cell death. In healthy human cells, AVEN plays a significant role in preventing apoptosis by interacting with apoptotic protease activating factor 1 (Apaf-1) and Bcl-xL, thereby inhibiting the activation of caspases, which are essential for the execution of apoptosis (Muther2017An; Assem2009Aven). This anti-apoptotic function is crucial for maintaining cell survival and homeostasis, particularly in tissues such as the epidermis, where AVEN is expressed and helps maintain normal epidermal function by preventing excessive apoptosis (Muther2017An).

AVEN is primarily active in the cytoplasm, where it exerts its protective effects against apoptosis. Its expression is regulated by microRNAs, such as miR-30a, which can target AVEN and reduce its expression, leading to increased apoptosis in certain contexts, such as aged skin (Muther2017An). The repression of AVEN by miR-30a is associated with aging features in the epidermis, highlighting its role in skin homeostasis and aging (Muther2017An). Overall, AVEN's function in inhibiting apoptosis is vital for the survival and proper functioning of various cell types, contributing to organismal development and homeostasis.

## Clinical Significance
Alterations in the expression of the AVEN gene have been implicated in various cancers, including osteosarcoma and leukemia. In osteosarcoma, high levels of AVEN expression are associated with lower metastasis-free survival and increased expression in metastatic lesions compared to primary tumors. Silencing AVEN in osteosarcoma cells leads to G2 cell-cycle arrest and affects the ATR-Chk1 DNA damage response, suggesting that AVEN is crucial for cell proliferation and resistance to chemotherapy (Baranski2015Aven‐mediated).

In acute lymphoblastic leukemia (ALL), AVEN is overexpressed and serves as a prognostic factor for poor outcomes. It plays a role in inhibiting apoptosis by stabilizing the pro-survival protein Bcl-xL and inhibiting the pro-apoptotic protein Apaf-1. AVEN's involvement in translational control of mRNAs with G-quadruplex structures, particularly those encoding mixed lineage leukemia (MLL) proto-oncogenes, is crucial for the progression of leukemia (Thandapani2015Aven).

In breast cancer, AVEN stabilizes Bcl-xL protein levels, preventing DNA damage-induced apoptosis. This interaction is specific to Bcl-xL, and AVEN's overexpression can lead to resistance against apoptosis-inducing treatments (Kutuk2010Aven). These findings suggest that AVEN's expression and interactions are critical in cancer progression and treatment resistance.

## Interactions
AVEN, a protein known for its role in inhibiting apoptosis, participates in several significant interactions with other proteins and nucleic acids. It interacts with Bcl-xL, a member of the Bcl-2 family, through a yeast two-hybrid strategy, which highlights its role in antiapoptotic functions by preventing caspase activation (Chau2000Aven). AVEN also binds to Apaf-1, inhibiting its oligomerization and thus regulating caspase-9 activation, which is crucial for apoptosis regulation (Esmaili2010Regulation; Chau2000Aven).

In the context of DNA damage response, AVEN interacts with ATM kinase, acting as both an activator and a substrate. This interaction is crucial for ATM activation, which is necessary for cell-cycle arrest following DNA damage (Guo2008AvenDependent). AVEN's phosphorylation by ATM enhances its ability to activate ATM, suggesting a positive feedback loop (Guo2008AvenDependent).

AVEN also interacts with RNA G-quadruplex (G4) structures through its RGG/RG motifs, which are essential for its role in translational regulation. This interaction is independent of arginine methylation, although AVEN's interaction with Tudor domain-containing proteins like TDRD3 and SMN is methylation-dependent (Thandapani2015Aven). These interactions highlight AVEN's multifaceted role in regulating apoptosis, cell cycle progression, and translation.


## References


[1. (Kutuk2010Aven) Ozgur Kutuk, Sehime Gulsun Temel, Sahsine Tolunay, and Huveyda Basaga. Aven blocks dna damage-induced apoptosis by stabilising bcl-xl. European Journal of Cancer, 46(13):2494–2505, September 2010. URL: http://dx.doi.org/10.1016/j.ejca.2010.06.011, doi:10.1016/j.ejca.2010.06.011. This article has 28 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.ejca.2010.06.011)

[2. (Assem2009Aven) Magda Assem, Thorraya Abedel- ALhameid, Gihan A-Basset, Amany Hilal, Mahmoud Kamel, Iman Khalil, Nahla Alsharkawey, and Ayman Metwally. Aven and survivin expression in egyptian acute leukemia and their relation to apoptosis. Nature Precedings, September 2009. URL: http://dx.doi.org/10.1038/npre.2009.3771.1, doi:10.1038/npre.2009.3771.1. This article has 0 citations.](https://doi.org/10.1038/npre.2009.3771.1)

[3. (Thandapani2015Aven) Palaniraja Thandapani, Jingwen Song, Valentina Gandin, Yutian Cai, Samuel G Rouleau, Jean-Michel Garant, Francois-Michel Boisvert, Zhenbao Yu, Jean-Pierre Perreault, Ivan Topisirovic, and Stéphane Richard. Aven recognition of rna g-quadruplexes regulates translation of the mixed lineage leukemia protooncogenes. eLife, August 2015. URL: http://dx.doi.org/10.7554/elife.06234, doi:10.7554/elife.06234. This article has 82 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.06234)

[4. (Muther2017An) Charlotte Muther, Lara Jobeili, Maëlle Garion, Sandrine Heraud, Amélie Thepot, Odile Damour, and Jérôme Lamartine. An expression screen for aged-dependent micrornas identifies mir-30a as a key regulator of aging features in human epidermis. Aging, 9(11):2376–2396, November 2017. URL: http://dx.doi.org/10.18632/aging.101326, doi:10.18632/aging.101326. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.18632/aging.101326)

[5. (Guo2008AvenDependent) Jessie Yanxiang Guo, Ayumi Yamada, Taisuke Kajino, Judy Qiju Wu, Wanli Tang, Christopher D. Freel, Junjie Feng, B. Nelson Chau, Michael Zhuo Wang, Seth S. Margolis, Hae Yong Yoo, Xiao-Fan Wang, William G. Dunphy, Pablo M. Irusta, J. Marie Hardwick, and Sally Kornbluth. Aven-dependent activation of atm following dna damage. Current Biology, 18(13):933–942, July 2008. URL: http://dx.doi.org/10.1016/j.cub.2008.05.045, doi:10.1016/j.cub.2008.05.045. This article has 36 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cub.2008.05.045)

[6. (Chau2000Aven) B.Nelson Chau, Emily H.-Y. Cheng, Douglas A. Kerr, and J.Marie Hardwick. Aven, a novel inhibitor of caspase activation, binds bcl-xl and apaf-1. Molecular Cell, 6(1):31–40, July 2000. URL: http://dx.doi.org/10.1016/S1097-2765(05)00021-3, doi:10.1016/s1097-2765(05)00021-3. This article has 302 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/S1097-2765(05)00021-3)

[7. (Baranski2015Aven‐mediated) Zuzanna Baranski, Tijmen H Booij, Anne‐Marie Cleton‐Jansen, Leo S Price, Bob van de Water, Judith VMG Bovée, Pancras CW Hogendoorn, and Erik HJ Danen. Aven‐mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. The Journal of Pathology, 236(3):348–359, March 2015. URL: http://dx.doi.org/10.1002/path.4528, doi:10.1002/path.4528. This article has 38 citations.](https://doi.org/10.1002/path.4528)

[8. (Esmaili2010Regulation) Armond M. Esmaili, Erika L. Johnson, Silpa S. Thaivalappil, Helena M. Kuhn, Sally Kornbluth, and Pablo M. Irusta. Regulation of the atm-activator protein aven by crm1-dependent nuclear export. Cell Cycle, 9(19):3913–3920, October 2010. URL: http://dx.doi.org/10.4161/cc.9.19.13138, doi:10.4161/cc.9.19.13138. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.4161/cc.9.19.13138)